Meeting
2024 ASCO Annual Meeting
Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Authors
Sarah Phillips
National Cancer Institute, Rockville, MD
Sarah Phillips , Rebecca Landy , Clara Bodelon , Mitchell J. Machiela , Sarah M. Temkin , Nicolas Wentzensen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Cancer Prevention
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10542)
DOI
10.1200/JCO.2024.42.16_suppl.10542
Abstract #
10542
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A re-analysis of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial accounting for ovarian cancer (OVCA) heterogeneity.
First Author: Sarah Madhu Temkin
Poster
2023 ASCO Annual Meeting
The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.
First Author: Chae Young Han
Poster
2023 ASCO Annual Meeting
Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations.
First Author: Matthew R Trendowski
Poster
2022 ASCO Genitourinary Cancers Symposium
The BARCODE1 study in primary care: Early results targeting men with increased genetic risk of developing prostate cancer—Examining the interim data from a community-based screening program using polygenic risk score to target screening.
First Author: Jana Kathlyn McHugh